Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL
Founder-led company
Madrigal Pharmaceuticals stock price today
$385
+71.88
+22.96%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 11 hours
Madrigal Pharmaceuticals stock price monthly change
+9.53%
month
Madrigal Pharmaceuticals stock price quarterly change
+9.53%
quarter
Madrigal Pharmaceuticals stock price yearly change
+32.25%
year
Madrigal Pharmaceuticals key metrics
Market Cap | 6.59B |
Enterprise value | 3.72B |
P/E | -12.99 |
EV/Sales | N/A |
EV/EBITDA | -12.82 |
Price/Sales | N/A |
Price/Book | 20.32 |
PEG ratio | 0.73 |
EPS | -23.09 |
Revenue | N/A |
EBITDA | -450.33M |
Income | -444.27M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMadrigal Pharmaceuticals stock price history
Madrigal Pharmaceuticals stock forecast
Madrigal Pharmaceuticals financial statements
| Jun 2023 | 0 | -85.8M | |
|---|---|---|---|
| Sep 2023 | 0 | -98.74M | |
| Dec 2023 | 0 | -112.19M | |
| Mar 2024 | 0 | -147.54M |
| Dec 2023 | 0 | -112.19M | |
|---|---|---|---|
| Mar 2024 | 0 | -147.54M | |
| Sep 2025 | 97.45M | -100.75M | -103.38% |
| Dec 2025 | 130.97M | -78.63M | -60.04% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 302461000 | 198.95M | 65.78% |
|---|---|---|---|
| Sep 2023 | 237964000 | 215.71M | 90.65% |
| Dec 2023 | 640547000 | 235.21M | 36.72% |
| Mar 2024 | 1082280000 | 231.52M | 21.39% |
| Jun 2023 | -75.31M | -3.73M | 42.93M |
|---|---|---|---|
| Sep 2023 | -84.92M | 50.19M | 19.58M |
| Dec 2023 | -79.93M | -362.12M | 479.91M |
| Mar 2024 | -149.15M | 98.05M | 573.70M |
Madrigal Pharmaceuticals alternative data
| Sep 2023 | 92 |
|---|---|
| Oct 2023 | 92 |
| Nov 2023 | 92 |
| Dec 2023 | 92 |
| Jan 2024 | 92 |
| Feb 2024 | 92 |
| Mar 2024 | 376 |
| Apr 2024 | 376 |
| May 2024 | 376 |
| Jun 2024 | 376 |
| Jul 2024 | 376 |
Madrigal Pharmaceuticals other data
100.00%
0.00%
of MDGL is owned by hedge funds
132
-9
12.14M
+190.25K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 1057692 | 0 |
| Apr 2024 | 0 | 252542 |
| May 2024 | 0 | 23525 |
| Jun 2024 | 0 | 3900 |
| Sep 2024 | 0 | 6363 |
| Nov 2024 | 0 | 14088 |
| Dec 2024 | 0 | 3600 |
| Patent |
|---|
Grant Utility: Targeted therapeutics Filling date: 19 Jun 2018 Issue date: 5 Jul 2022 |
Application Filling date: 7 Jul 2021 Issue date: 28 Oct 2021 |
Grant Filling date: 18 Oct 2017 Issue date: 17 Aug 2021 |
Application Filling date: 11 Dec 2020 Issue date: 3 Jun 2021 |
Application Filling date: 14 Aug 2020 Issue date: 13 May 2021 |
Application SOLID FORMS OF 2-(3,5-DICHLORO-4-((5-ISOPROPYL-6-OXO-1,6-DIHYDROPYRIDAZIN-3-YL)OXY)PHENY- L)-3,5-DIOXO-2,3,4,5-TETRAHYDRO-1,2,4-TRIAZINE-6-CARBONITRILE Filling date: 2 Jul 2019 Issue date: 29 Apr 2021 |
Application Filling date: 23 Sep 2020 Issue date: 25 Mar 2021 |
Grant Filling date: 1 Jul 2019 Issue date: 19 Jan 2021 |
Grant Utility: Targeted therapeutics Filling date: 8 Mar 2016 Issue date: 10 Nov 2020 |
Application Filling date: 26 May 2020 Issue date: 8 Oct 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q1 2022 9 May 2022 | Q1 2022 Earnings Call Transcript |
| Q2 2015 6 Aug 2015 | Q2 2015 Earnings Call Transcript |
| Q1 2015 7 May 2015 | Q1 2015 Earnings Call Transcript |
Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further
Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term
Altimmune: Deciphering The MASH Crash (Rating Upgrade)
Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide
Is Novo Nordisk Immune To President Trump's Drug Price Plans
In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals
89bio: A Buy With Strong Market Opportunity In MASH And SHTG
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
89bio's Pegozafermin Is Now Gaining Momentum
-
What's the price of Madrigal Pharmaceuticals stock today?
One share of Madrigal Pharmaceuticals stock can currently be purchased for approximately $385.
-
When is Madrigal Pharmaceuticals's next earnings date?
Unfortunately, Madrigal Pharmaceuticals's (MDGL) next earnings date is currently unknown.
-
Does Madrigal Pharmaceuticals pay dividends?
No, Madrigal Pharmaceuticals does not pay dividends.
-
How much money does Madrigal Pharmaceuticals make?
Madrigal Pharmaceuticals has a market capitalization of 6.59B.
-
What is Madrigal Pharmaceuticals's stock symbol?
Madrigal Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "MDGL".
-
What is Madrigal Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Madrigal Pharmaceuticals?
Shares of Madrigal Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Madrigal Pharmaceuticals's key executives?
Madrigal Pharmaceuticals's management team includes the following people:
- Dr. Paul A. Friedman M.D. Chairman & Chief Executive Officer(age: 82, pay: $1,070,000)
- Dr. Rebecca A. Taub M.D. Founder, Chief Medical Officer, Pres of R&D and Director(age: 73, pay: $830,060)
- Mr. Remy Sukhija Senior Vice President & Chief Commercial Officer(age: 53, pay: $714,900)
- Mr. Brian J. Lynch Senior Vice President & Gen. Counsel(age: 63, pay: $698,050)
-
Is Madrigal Pharmaceuticals founder-led company?
Yes, Madrigal Pharmaceuticals is a company led by its founder Dr. Rebecca A. Taub M.D..
-
How many employees does Madrigal Pharmaceuticals have?
As Jul 2024, Madrigal Pharmaceuticals employs 376 workers.
-
When Madrigal Pharmaceuticals went public?
Madrigal Pharmaceuticals, Inc. is publicly traded company for more then 18 years since IPO on 6 Feb 2007.
-
What is Madrigal Pharmaceuticals's official website?
The official website for Madrigal Pharmaceuticals is madrigalpharma.com.
-
Where are Madrigal Pharmaceuticals's headquarters?
Madrigal Pharmaceuticals is headquartered at Four Tower Bridge, West Conshohocken, PA.
-
How can i contact Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals's mailing address is Four Tower Bridge, West Conshohocken, PA and company can be reached via phone at +267 8242827.
Madrigal Pharmaceuticals company profile:
Madrigal Pharmaceuticals, Inc.
madrigalpharma.comExchange:
NASDAQ
Full time employees:
376
Industry:
Biotechnology
Sector:
Healthcare
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-Ăź agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Four Tower Bridge
West Conshohocken, PA 19428
West Conshohocken, PA 19428
CIK: 0001157601
ISIN: US5588681057
CUSIP: 558868105
